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RESEARCH REPORT

High-throughput screening of clinically approved drugs that
prime polyethylenimine transfection reveals modulation of
mitochondria dysfunction response improves gene transfer
eﬃciencies
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Abstract
Nonviral gene delivery methods are advantageous over viral vectors in terms of safety, cost, and
ﬂexibility in design and application, but suﬀer from lower gene transfer eﬃciency. In addition to
modiﬁcations to nucleic acid design and nonviral carriers, new tools are sought to enhance transfection. Priming is the pharmacological modulation of transfection eﬃciency and transgene
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expression, and has demonstrated transfection increase in several compounds, for example, chloroquine and glucocorticoids. To develop a library of transfection priming compounds, a highthroughput screen was performed of the NIH Clinical Collection (NCC) to identify clinical compounds that prime polyethylenimine (PEI) transfection. HEK293T cells were treated with priming
compounds, then transfected with enhanced green ﬂuorescent protein (EGFP)-encoding plasmid by
PEI. After 48-hr culture, primed and transfected cells were assayed for transfection, cell proliferation, and cell viability by ﬂuorescence measurement of EGFP reporter, Hoechst 33342 nuclei stain,
and resazurin metabolic assay. From the microscope image analysis and microplate measurements,
transfection fold-changes were determined, and compounds resulting in statistically signiﬁcant
transfection fold-change were identiﬁed. NCC compounds were clustered using PubChem ﬁngerprint similarity by Tanimoto coeﬃcients in ChemmineTools. Fold-changes for each compound were
linked to drug clusters, from which drug classes that prime transfection were identiﬁed. Among the
identiﬁed drugs classes that primed transfection increases were antioxidants, GABAA receptor
modulators, and glucocorticoids. Resveratrol and piceid, stilbenoid antioxidants found in grapes,
and zolpidem, a GABAA modulator, increased transfection nearly three-fold. Literature indicate
interaction of the identiﬁed transfection priming drug clusters with mitochondria, which may modulate mitochondrial dysfunction known to be associated with PEI transfection.

KEYWORDS

high-throughput screen, mitochondrial dysfunction, NIH Clinical Collection, nonviral gene delivery,
polyethylenimine toxicity, priming transfection

1 | INTRODUCTION

transduction is limited by design constraints and safety concerns, a few of
which include: size of transgene,1 host immune response,2 and insertional

Gene delivery, the transfer of exogenous nucleic acids into cells to modify

mutagenesis.3 Nonviral gene delivery methods often make use of chemical

gene expression, can be accomplished with either viral or nonviral meth-

strategies that rely on cationic carriers, which can associate with nucleic

ods. Viral transduction is highly eﬃcient in vitro and in vivo, however,

acids to form complexes that achieve gene delivery.1 These materials oﬀer

C 2016 The Authors. Bioengineering & Translational Medicine is published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers
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advantages over viral methods of gene delivery, in safety, cost, fabrication,

expressed in successfully versus unsuccessfully transfected HEK293T

and ﬂexibility in design and application. However, compared to viral meth-

cells, was shown to enhance or decrease transgene expression,16–19

ods, chemical methods of nonviral gene delivery suﬀer from lower trans-

demonstrating that genomic targets can be modulated by priming to

fection eﬃciency, especially in vivo.4 Many barriers to successful

enhance nonviral gene delivery. Several of these genes were related to

transfection exist, with each contributing to the overall low eﬃciency of

cell stress, indicating that in addition to overcoming the primary bar-

nonviral gene delivery. Systemic barriers include serum stability, clearance,

riers to transfection, nonviral gene delivery strategies may need to

and targeting,5 while cellular barriers to eﬃcient transfection include cellu-

modulate the overall cellular response to transfection to achieve higher

lar internalization, endosomal escape, nuclear transport, nuclear import,

transfection eﬃciency and more sustained transgene expression.

and transcriptional and translational regulation.5

While broad applicability of transfection priming to diﬀerent car-

Carrier properties and optimization are the most important determi-

riers, nucleic acids, and cell types has not been established, a next step

nants in the eﬃciency of chemical nonviral gene delivery strategies in

in the development of this strategy is to search for other compounds

terms of facilitating delivery to and into cells. In 1995, Polyethylenimine

that have priming eﬀects. Priming strategies can theoretically be used

(PEI), a cationic polymer, demonstrated successful transfection in vitro

to modulate any of the known barriers to transfection, from transport

and in vivo in multiple cell types.6 General optimization of PEI transfec-

mechanisms into the cell and to the nucleus, to transcriptional and

tion is accomplished through tuning of N:P ratio, the ratio of amine

translational regulation and toxicity. To broadly search for potential pri-

groups in the PEI polymer to phosphate groups in the nucleic acid. N:P

ming mechanisms, a high-throughput, drug repurposing approach was

ratio determines the overall size and charge of these PEI-nucleic acid
complexes and deﬁnes their ability to circulate in serum, internalize into
cells, and escape endosomes, and thus are primary determinants of PEI
transfection eﬃciency.6–8 Optimized PEI transfection achieves eﬃciency

taken toward generating a library of compounds from the NIH Clinical
Collection (NCC)20 that possess clinically relevant bioavailability and
biocompatibility, and whose priming eﬀects could be studied and used
to develop eﬀective nonviral gene delivery strategies.

of 50–80% in vitro depending on molecular weight of PEI, plasmid, and
cell type,8 compared to the 100% eﬃciency achieved by some optimized viral transduction methods in vitro.9 Most attempts to improve
chemical methods of nonviral gene delivery involve modiﬁcation of the
carriers, such as modiﬁcation of PEI with PEG and targeting ligands8 to
increase serum stability and circulation or enhance speciﬁc uptake,

2 | MATERIALS AND METHODS
2.1 | HEK293T culture and transfection reagents
HEK293T cells (ATCC, Manassas, VA) were cultured in T-25 ﬂasks

respectively. Although nonviral gene delivery methods continue to be

(Thermo Fisher Scientiﬁc, Waltham, MA) in Dulbecco’s Modiﬁed Eagle

improved, they have not exceeded viral methods in gene transfer eﬃ-

Medium (DMEM) (Life Technologies, Carlsbad, CA) completed with

ciency and sustained expression in clinical trials.10

10% fetal bovine serum (Life Technologies), 1% Penicillin/Streptomycin

We propose pharmacological priming as an adjuvant strategy,

(Life Technologies), and 1% sodium pyruvate (Life Technologies). Cells

which can, in conjunction with innovations in carrier and nucleic acid

were incubated at 378C, 5% CO2, and passaged using 1 mM EDTA in

design, achieve clinically relevant nonviral gene transfer eﬃciency and

PBS (Sigma-Aldrich, St. Louis, MO) at 75–85% conﬂuence approxi-

expression. Priming refers to the treatment of cells with chemical com-

mately every 48 hrs.

pounds before, during, or after delivering carrier-nucleic acid complexes

The pEGFPLuc plasmid delivered in this transfection screen enco-

to cells in order to improve some aspect of the gene transfer process.

des for a fusion protein of enhanced green ﬂuorescent protein (EGFP)

Priming enhancement of transfection eﬃciency and transgene expres-

and luciferase, driven by a CMV promoter (Clontech, Mountain View,

sion can be achieved through direct modulation of the barriers to gene

CA). pEGFPLuc was propagated in E. coli, selected by kanamycin treat-

delivery, or indirectly through modulation of the cellular response to

ment, isolated using Qiagen Giga Prep kits (Qiagen, Valencia, CA), pre-

transfection in terms of toxicity and altered gene expression.

pared in endotoxin-free TE buﬀer at 1 mg/ml, and subsequently stored

Priming compounds for gene delivery have been used in the litera-

in frozen aliquots at 2208C. PEI (25 kDa branched PEI, Sigma-Aldrich)

ture, mostly in the context of probing biological mechanisms of trans-

was used for this transfection screen. PEI was prepared at 1 mg/ml, in

fection. For example, chloroquine is an antimalarial compound that has

0.1 M sodium bicarbonate (pH 8.2), then stored in aliquots at 2808C.

been demonstrated to enhance nonviral gene delivery in transfections
across several nanoparticle carrier formulations,11 through buﬀering of
endosomes, aiding complexes in escaping endosomes and avoiding
lysosomal degradation.11,12 Glucocorticoid priming has been demon-

2.2 | Priming compounds and ﬂuorescence assay
reagents

strated to enhance viral and nonviral gene delivery across multiple cell

The NIH NCC, which contains 725 compounds screened for transfec-

types.13–15 Recent work showed that priming human mesenchymal

tion priming, were received in ten, 96-well plates, with 10 ll of each

stem cells (hMSCs), a primary cell type that is typically diﬃcult to trans-

compound at 10 mM in dimethyl sulfoxide (DMSO). To prepare ali-

fect, with dexamethasone (a synthetic glucocorticoid), increased trans-

quots, 2 ll of each compound were prepared in four 96-well aliquot

fection eﬃciency and transgene expression up to 10-fold across

plates per original NCC plate, and kept frozen at 2208C. Hoechst

multiple donors.15 Furthermore, pharmacological priming, with activa-

33342 ﬂuorescent dye was used to stain cell nuclei and enable cell-

tors and inhibitors of genes previously identiﬁed as diﬀerentially

count by processing of ﬂuorescence microscope images, while
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resazurin was used as a ﬂuorescent metabolic indicator in this screen.

plugin was adjusted to optimize detection and minimize misidentiﬁca-

For cell staining, Hoechst 33342 stock solution was prepared from

tion of nuclei and EGFP cells.

lyophilized powder (Sigma-Aldrich), dissolved in ddH20 at a concentra-

In addition to microscope imaging, EGFP, Hoecshst, and resazurin

tion of 10 mg/ml, and stored at 48C. Stock resazurin solution was pre-

ﬂuorescence were measured by Synergy H1 plate reader (BioTek,

pared from lyophilized resazurin sodium salt powder (Sigma-Aldrich),

Winooski, VT), with excitation/emission settings of 475 nm/509 nm,

dissolved in PBS at a concentration of 10 mg/ml, and stored at 48C.

355 nm/464 nm, and 545 nm/590 nm, and gain settings of 100, 50,
and 50, respectively. Nine measurements were taken per well in a

2.3 | Transfection priming high-throughput screen
HEK293T cells were detached from culture ﬂasks by EDTA, counted by
hemocytometer, and seeded at 25,000 cells/cm2 (8,000 cells per well in
80 ll) into 96-well plates. Four plates were seeded for each of the 10

three by three array equally spaced within the well, from which mean
intensities were calculated.

2.4 | Data processing

plates of the NCC collection screened, for duplicate testing of the com-

The goal of the data processing was to determine compounds that pro-

pounds at 5 and 50 lM. Seeded plates were cultured at 378C, 5% CO2,

duced fold-changes in transfection, compared to vehicle controls. To

and approximately 17 hr after seeding two plates with cells, 40 ll of

reduce potential fold-change bias resulting from initial seeding density

each NCC compound were delivered into corresponding wells of both

variation, vehicle control wells that had total cell-counts less than the

seeded plates, at either 5 or 50 lM ﬁnal well volume concentration.

mean cell-count of vehicles controls as a whole for the plate were dis-

Two columns (16 wells) of each plate received equivalent DMSO %

carded from consideration for calculations of fold-changes. There

instead of NCC compound as priming vehicle controls. The primed

remained up to 16 vehicle control wells per plate in the screen after ﬁl-

plates were then incubated for one hour at 378C, 5% CO2 before trans-

tering (n  16). Image and plate reader data for each well were then

fection. For transfection, PEI was diluted in 1X Tris-buﬀered saline

normalized by cell-count and their fold-changes determined relative to

(TBS) and added to pEGFPLuc diluted in 1X TBS. Complexes were

these ﬁltered vehicle control wells. EGFP measurements were normal-

formed at an optimized (data not shown) N:P of 15 to deliver 0.17 lg

ized into two separate measures: normalization by total cell-count and

of pEGFPLuc in 21 ll of TBS to each well 1 hr after priming, followed

normalization by transfected cell-count. Hoechst and resazurin meas-

by incubation at 378C, 5% CO2 for 48 hr before staining and imaging.

urements were normalized by total cell-count.

The primed and transfected HEK293T plates were stained with

Cytotoxicity ﬁlters were implemented to remove from consideration

Hoechst and resazurin ﬂuorescent dyes to enable subsequent nuclei

compounds that were too toxic at the tested concentrations to warrant

counts and viability assessments, respectively, multiplexed with the

further consideration in the screen. In the ﬁrst toxicity ﬁlter, compounds

EGFP ﬂuorescent reporter for transgene expression. Staining solution

with normalized Hoechst-count fold-change of less than 0.2 were dis-

consisted of 17.5 lg/ml Hoechst 33342 and 10 lg/ml resazurin in Flu-

carded. In the second toxicity ﬁlter, compounds with Hoechst-count

orobrite DMEM (Thermo Fisher Scientiﬁc). After rinsing cells with PBS,

fold-change two or three standard deviations below the plate-wide aver-

100 ll of the staining solution was added to each well, followed by

age of Hoechst-count fold-changes greater than 0.2 were also discarded.

incubation for 30 min at 378C, 5% CO2.

A more stringent toxicity ﬁlter was used for the 5 lM concentration

After incubation with the staining solution, plates were imaged using

(two standard deviations) than the 50 lM (three standard deviations).

a DMI3000B manual inverted microscope with DFC340FX digital cam-

The rationale behind this diﬀerence is that the 5 lM conditions contain

era, EL-6000 mercury halide lamp for ﬂuorescence excitation, and LAS

a lower concentration of priming compound and of the DMSO vehicle,

software V4.0 for digital image viewing and capture (Leica, Buﬀalo Grove,

resulting in less cytotoxicity than the 50 lM conditions; therefore, a

IL). Filters for excitation and detection at the EGFP and Hoechst wave-

more stringent ﬁlter was applied to the lower concentration.

lengths (488 nm/509 nm and 355 nm/465 nm, respectively) were used

Each compound was tested in a single well per plate, in duplicate

to take monochrome images of their ﬂuorescence, in addition to phase

plates, at 5 and 50 lM concentrations. The duplicate normalized fold-

contrast images. Images were taken with a 5x objective at the center of

changes of these single wells from duplicate plates were grouped

each well in 8-bit TIFF format and 1600x1200 pixels, with each pixel

(n 5 2) for unpaired one-tailed t tests against grouped ﬁltered vehicle

having a greyscale value from 0 to 255. Consistent ﬂuorescence excita-

controls from the same duplicate plates (n  32 ﬁltered vehicle control

tion lamp intensity and camera exposure settings were used to allow for

wells from the duplicate plates associated with the tested compound

comparison of image intensities between wells in the same plate.

of n  16 control wells each), to obtain p values for EGFP, Hoechst,

21

a Java-based image processing program, were

and resazurin measurements of each compound at each concentration,

used to automate the mean ﬂuorescence intensity measurements and

with an a-value for signiﬁcance of 0.05. For each well, the assumption

Macros in ImageJ,

maxima counts for the processing of the thousands of images acquired

of equal or unequal variance in the t test was estimated by F-test (one-

over the course of the screen. Average grey values of the Hoechst and

tailed, a 5 0.05) for equality of variances between tested compound

EGFP images were determined using the “Measure” plugin in ImageJ.

and control wells. One-tailed t tests were used to score the screen

Total cells and transfected cells were counted for each well using the

fold-changes, in spite of expected higher false positive rates than two-

“Find Maxima” plugin to count Hoechst stained nuclei and EGFP

tailed tests, to err on the side of caution in not rejecting potential pri-

expressing cells, respectively. The noise tolerance of the “Find Maxima”

ming compounds, and rely on the clustering results to support the
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Highest fold-changes in transfection priming hits at 5mM of NCC compounds

Transfection
fold-increase

Transfection
fold-decrease

Transfectiona

Cell-countb

Hoechst-intensityc

Resazurin-intensityd

GABA receptor
modulator

3.05

0.52

Resveratrol

Stilbenoid

3.04

0.55

Tropisetron
hydrochloride

Serotonin receptor
antagonist

2.67

0.97

0.91

1.07

Tranilast

Anti-allergy

Lansoprazole

Proton-pump
inhibitor

2.17

0.74

1.11

1.29

2.13

0.72

1.13

1.42

Nobiletin
Nitrazepam

Flavonoid

2.08

0.61

1.23

1.21

GABA receptor
modulator

2.03

0.53

Enalaprilat

Angiotensinconverting-enzyme
inhibitor pro-drug

2.00

0.55

1.35

1.51

Droperidol

Dopamine receptor
antagonist

1.95

0.52

Mestanolone

Androgen hormone

1.93

0.61

1.26

Epigallocatechin
gallate

Flavonoid

0.08

1.37

0.88

Ampiroxicam

Nonsteroidal
anti-inﬂammatory drug

0.31

0.93

0.91

Nimodipine

Calcium channel
blocker

0.35

0.90

(2)-Cotinine

Nicotine metabolite

0.41

0.87

Ramipril

Angiotensinconverting-enzyme
inhibitor

0.42

0.98

Desloratadine

Anti-histamine

0.50

0.86

Crotamiton

Anti-itch

0.50

0.98

Guanidine

Amino acid
metabolite

0.52

0.93

Letrozole

Estrogen synthesis
inhibitor

0.52

1.00

0.87

Fluphenazine
hydrochloride

Dopamine receptor
antagonist

0.53

0.85

1.08

Compound

Drug type

Zolpidem tartrate

1.14

1.16
0.92

1.19
0.93
1.12

1.17

Note. Empty values indicate nonsigniﬁcant fold-change.
Transfection fold-changes were calculated from duplicate averages of EGFP ﬂuorescence, measured by EGFP cell-count (image processing) or EGFP
intensity (plate reader and image processing), relative to the same measurement averaged from the vehicle controls in each compound’s respective
plates. These measurements were normalized in two separate ways, total cell-count (determined by Hoechst-count), and transfected cell-count (determined by EGFP-count), for measurement of transfection per cell as well as transfection per transfected cell.
b
Cell-count fold-changes were calculated from duplicate averages of image processing measurements of Hoechst-count relative to the average
Hoechst-count measurements of vehicle controls in each compound’s respective plates. Cell-count fold-changes are shown for each hit presented as a
general toxicity reference, not to imply signiﬁcant increase or decrease.
c
Hoechst-intensity fold changes were calculated from duplicate averages of plate reader or image processing measurements of Hoechst-intensity normalized by total cell-count (determined by Hoechst-count), relative to the average Hoechst-intensity measurements of vehicle controls in each compound’s respective plates.
d
Resazurin-intensity fold changes were calculated from duplicate averages of plate reader measurements of resazurin intensity normalized by cell-count
(determined by Hoechst-count), relative to the average resazurin-intensity measurements of vehicle controls in each compound’s respective plates.
a

single compound hit selection as well as future investigation of the

test in small sample sizes, sacriﬁcing power for breadth of small mole-

screen hits to reject false positives.

cules tested from the NCC.

Given the large number of drugs to be tested in the NCC, we
chose to use a sample size of two for each concentration of each drug.
Two is the minimum number of samples for performing a t test22; more

2.5 | Hit selection and compound clustering

importantly, the goal of this screen was to be the initial step in the

All NCC compounds that exhibited signiﬁcant fold-increases or fold-

search for clinical compounds that could be repurposed toward trans-

decreases in transfection, at either 5 or 50 lM, and were not ﬁltered

fection priming, using a high throughput methodology to deliberately

for cytotoxicity, were identiﬁed as hits (a-value for signiﬁcance of

NGUYEN

|

ET AL.

T A B LE 2

127

Highest fold-changes in transfection priming hits at 50 mM of NCC compounds

Transfection foldincrease

Transfection folddecrease

Compound

Drug type

Transfectiona

Cell-countb

Tranilast

Anti-allergy

3.63

0.55

Hoechst-intensityc

Resazurin-intensityd
1.24

Piceid

Stilbenoid

2.63

0.69

1.17

5-Fluorocytosine

Pyrimidine analogue

2.54

0.52

1.50

Cinanserin

Serotonin receptor
antagonist

2.53

0.63

1.41

Zardaverine

Phosphodiesterase
inhibitor

2.26

0.55

1.36

Nateglinide

ATP potassium
channel closer

2.08

0.51

1.23

1.21

Eryped

Macrolide antibiotic

1.99

0.72

1.26

1.26

Mestinon

Cholinesterase
inhibitor

1.83

0.77

1.21

1.23

Acyclovir

DNA polymerase
inhibition (anti-viral)

1.78

0.60

Stiripentol

GABA receptor
modulator

1.77

0.72

Epigallocatechin
gallate

Flavonoid

0

0.80

1.58

1.23

Ceﬁxime trihydrate

b-lactam antibiotic

0.017

1.45

0.84

Cefdinir

b-lactam antibiotic

0.032

1.35

0.88

Cefuroxime

b-lactam antibiotic

0.039

1.39

Rolitetracycline

Tetracycline
antibiotic

0.063

1.42

0.86

Cefatrizine propylene glycol

b-lactam antibiotic

0.095

1.75

0.78

Tetracycline

Tetracycline
antibiotic

0.139

1.08

0.85

Taxifolin-(1)

Flavonoid

0.162

1.22

0.87

(1/2)-Epinephrine
hydrochloride

Adrenergic receptor
agonist

0.35

1.36

0.83

Isoquercitrin
Hyperoside

Flavonoid
Flavonoid

0.358

1.68

0.86

Note. Empty values indicate nonsigniﬁcant fold-change.
a
Transfection fold-changes were calculated from duplicate averages of EGFP ﬂuorescence, measured by EGFP cell-count (image processing) or EGFP
intensity (plate reader and image processing), relative to the same measurement averaged from the vehicle controls in each compound’s respective
plates. These measurements were normalized in two separate ways, total cell-count (determined by Hoechst-count), and transfected cell-count (determined by EGFP-count), for measurement of transfection per cell as well as transfection per transfected cell.
b
Cell-count fold-changes were calculated from duplicate averages of image processing measurements of Hoechst-count relative to the average
Hoechst-count measurements of vehicle controls in each compound’s respective plates. Cell-count fold-changes are shown for each hit presented as a
general toxicity reference, not to imply signiﬁcant increase or decrease.
c
Hoechst-intensity fold changes were calculated from duplicate averages of plate reader or image processing measurements of Hoechst-intensity normalized by total cell-count (determined by Hoechst-count), relative to the average Hoechst-intensity measurements of vehicle controls in each compound’s respective plates.
d
Resazurin-intensity fold changes were calculated from duplicate averages of plate reader measurements of resazurin intensity normalized by cell-count
(determined by Hoechst-count), relative to the average resazurin-intensity measurements of vehicle controls in each compound’s respective plates.

0.05). In addition, the hit selection of this screen also included examina-

single linkage ﬁngerprint similarity determined by Tanimoto coeﬃ-

tion of overall transfection fold-changes of grouped drug clusters to

cient thresholds of 0.4 to 0.9 (higher coeﬃcient indicates greater

identify drug classes for which the majority of compounds were hits

ﬁngerprint similarity).

for transfection priming eﬀects. NCC compounds were clustered

EGFP, Hoechst, and resazurin measurement fold-changes for each

using the Chemmine Tools web platform for comparison of Pub-

compound at each concentration were linked to the NCC clusters by a

Chem ﬁngerprints by Tanimoto coeﬃcients.23 Hierarchical clustering

custom Perl script, which parsed the data ﬁles and grouped the data

was used to create a dendrogram based on single linkage ﬁngerprint

into average fold-changes for each binned cluster. To analyze the hits,

similarity, while binning clustering grouped compounds based on

the compounds which primed the 10 highest fold-increases or fold-
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Average fold-changesa of transfection priming hits from clusters of interest (Figure 2)
Transfection fold-increase hits

Cluster (#)
Hormones (54)

Glucocorticoids (30)

Tetracyclines (6)

Fluoroquinolones (8)
b-lactams (18)

Cephalosporins (10)

Macrolides (4)

Flavonoids and Stilbenoids (13)

GABA modulators (9)

Concentration

# of hits

Transfectionb

Transfection fold-decrease hits
Cell-countc

# of hits

Transfectionb

Cell-countc

5 mM

34*

1.43 6 0.22

0.73 6 0.15

3

0.81 6 0.07

0.93 6 0.19

50 mM

15

1.35 6 0.16

0.66 6 0.86

9

0.74 6 0.12

0.84 6 0.24

5 mM

17*

1.37 6 0.14

0.77 6 0.14

3

0.81 6 0.07

0.93 6 0.19

50 mM

12

1.37 6 0.15

0.67 6 0.10

3

0.81 6 0.04

1.01 6 0.08

5 mM

5*

1.27 6 0.15

0.82 6 0.06

1

0.91

0.72

3*

0.26 6 0.27

1.07 6 0.36

0.65 6 0.21

0.96 6 0.09

50 mM

0

5 mM

5*

1.54 6 0.24

0.64 6 0.17

0

50 mM

4

1.56 6 0.25

0.63 6 0.11

2

5 mM

7

1.25 6 0.17

0.93 6 0.13

2

0.69 6 0.12

1.26 6 0.14

50 mM

5

1.25 6 0.11

0.96 6 0.20

9*

0.42 6 0.37

1.31 6 0.21

5 mM

4

1.33 6 0.19

0.85 6 0.09

1

0.61

1.36

50 mM

1

1.19

1.08

7*

0.31 6 0.35

1.35 6 0.22

5 mM

3*

1.24 6 0.05

0.82 6 0.19

0

50 mM

2*

1.72 6 0.39

0.63 6 0.12

2*

0.74 6 0.18

0.85 6 0.42

5 mM

3

2.1 6 0.86

0.72 6 0.37

4

0.52 6 0.33

1.04 6 0.51

50 mM

3

2.04 6 0.61

0.69 6 0.09

4

0.32 6 0.32

1.26 6 0.36

5 mM

7*

1.74 6 0.63

0.66 6 0.14

0

50 mM

4

1.41 6 0.25

0.72 6 0.04

0

Note. Nobileton, a ﬂavonoid (Table 1), was not automatically grouped into the ﬂavonoid and stilbenoid cluster (Figure 2) by the clustering algorithm; it
was manually added to the ﬂavonoid and stilbenoid cluster for the calculation of cluster average fold-changes. Similarly, stiripentol (Table 2) and zolpidem (Table 1) are GABAA receptor modulators which were not automatically clustered with the benzodiazepines (Figure 2); their fold-changes were
included into the GABAA modulator cluster for calculation of cluster average fold-changes (Table 3).
a
Average fold-changes are shown as mean 6 standard deviation.
b
Transfection fold-changes of hits from the same cluster were averaged. The transfection fold-changes of hits were calculated from duplicate averages
of EGFP ﬂuorescence, measured by EGFP cell-count (image processing) or EGFP intensity (plate reader and image processing), relative to the same
measurement averaged from the vehicle controls in each compound’s respective plates. These measurements were normalized in two separate ways,
total cell-count (determined by Hoechst-count) and transfected cell-count (determined by EGFP-count), for measurement of transfection per cell as
well as transfection per transfected cell.
c
Cell-count fold-changes of hits from the same cluster were averaged. The cell-count fold-changes were calculated from duplicate averages of image
processing measurements of Hoechst-count relative to the average Hoechst-count measurements of vehicle controls in each compound’s respective
plates. Average cell-count fold-changes are shown for clustered hits as a general toxicity reference, not to imply signiﬁcant increase or decrease.
*The majority of compounds in the cluster were hits for this fold-change.
#
Denotes the number of NCC compounds in the cluster.

decreases in transfection at either 5 or 50 lM were determined (Tables

3 | RESULTS

1 and 2), which were used to determine clusters of interest (Figure 2).
The grouped fold-changes in transfection of the clusters of interest

HEK293T cells were primed with 725 compounds from the NCC,

were examined to determine clusters for which the majority of member

transfected with a plasmid encoding for an EGFP reporter protein using

compounds were hits for priming transfection (Table 3).

25 kDa branched PEI, and assayed by ﬂuorescence microscope imaging
and plate reader measurement of EGFP, Hoechst 33342, and resazurin,

2.6 | Preliminary veriﬁcation experiment

to screen for compounds that enhance or decrease transfection, without signiﬁcant toxicity (see Supporting Information Tables S1–S4 for

Preliminary veriﬁcation experiments were performed for three of the

the EGFP and Hoechst ﬂuorescence intensity and count data of the

priming compounds identiﬁed (resveratrol, epigallocatechin gallate

compounds listed in Tables 1 and 2). With an a-value for signiﬁcance

[EGCG], and corticosterone), testing these hit compounds at 5 lM in

of 0.05 for average fold-changes of duplicates and two toxicity ﬁlters,

triplicate in 48-well plates, with number of seeded cells and volumes of

the screen returned 441 priming compound hits at 5 mM with EGFP

reagents added scaled by the well surface area increase from 96-well

fold-change ranging from 0.077 to 4.29, and Hoechst-count fold-

plates (see complete description of the method in Supporting Informa-

changes ranging from 0.22 to 1.45 (Figures 1A and 1B). There were

tion). Transgene expression was assayed by luciferase assay, normal-

333 hits at 50 mM, with EGFP fold-change ranging from 0 to 3.63,

ized by total protein measured by BCA assay, in units of relative light

and Hoechst-count fold-changes ranging from 0.25 to 1.75 (Figures 1C

units per milligram of total protein.

and 1D).

NGUYEN

|

ET AL.

129

EGFP transfection fold-changes versus Hoechst-count fold-changes are shown for (A) 369 hits with fold-increases in transfection at 5 mM, (B) 72 hits with fold-decreases in transfection at 5 mM, (C) 201 hits with fold-increases in transfection at 50mM, and (D) 132
hits with fold-decreases in transfection at 50 mM. To examine eﬀect of transfection priming on cell proliferation, linear regressions were
performed, demonstrating negative correlation for transfection fold-increases (AC) and no correlation for transfection fold-decreases (BD).
Regression slopes are displayed as the 95% conﬁdence interval, along with R2 for goodness of ﬁt. The dashed lines indicate the Hoechstcount fold-change threshold of greater than 0.5 used in determining the largest transfection fold-increases and fold-decreases of hits in the
screen (Tables 1 and 2).
FIGURE 1

At 5 mM, there were 369 hits with transfection fold-increases

and 1C). There were no correlations of EGFP fold-decreases versus

(1.45 6 0.34 fold-change, mean 6 standard deviation) and 72 hits

Hoechst-count fold-change at either 5 or 50 mM, R2 5 0.003 and

with transfection fold-decreases (0.73 6 0.17 fold-change) (Figures

0.056, respectively (Figures 1B and 1D).

1A and 1B). At 50 mM, there were 201 hits with transfection fold-

To further analyze the transfection priming hits, drugs within the

increases (1.47 6 0.35 fold-change) and 132 hits with transfection

NCC were clustered into groups of similar compounds by binning clus-

fold-decreases (0.69 6 0.20 fold-change) (Figures 1C and 1D). To

tering of PubChem ﬁngerprints at Tanimoto clustering coeﬃcient

identify the most eﬀective priming compounds from the hundreds

thresholds ranging from 0.4 to 0.9. Cluster number increases as cluster-

of hits, the 10 compounds that resulted in the largest EGFP fold-

ing coeﬃcient for similarity is increased, from 300 clusters at clustering

change, in fold-increase or fold-decrease in transfection, with

coeﬃcient 0.4, to 619 clusters at clustering coeﬃcient 0.9. Based on

Hoechst-count fold-change no less than 0.5, were identiﬁed at 5 mM

the identiﬁcation of compounds that had the most increased or

(Table 1) and 50 mM (Table 2).

decreased transfection fold-changes (Tables 1 and 2) clusters of inter-

Linear regressions of EGFP fold-change versus Hoechst-count

est were identiﬁed (Figure 2), including antibiotics (tetracyclines,

fold-change were performed to determine correlations between trans-

b-lactams, and macrolides), ﬂavonoids, stilbenoids, and GABA receptor

fection priming and cell proliferation. There were negative correlations

modulators. For these clusters of interest, average transfection fold-

between EGFP fold-increases versus Hoechst-count fold-change at

changes and average Hoechst-count fold-changes were determined

both 5 and 50 mM, with R 5 0.467 and 0.401, respectively (Figures 1A

(Table 3).

2
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Dendrograms illustrate hierarchical clustering of hormones (A), tetracyclines (B), ﬂuoroquinolones (C), b-lactams (D), macrolides
(E), ﬂavonoids and stilbenoids (F), and benzodiazepine GABAA receptor modulators (G), from the NCC, annotated with Tanimoto coeﬃcients
to indicate degree of similarity between compounds in the clusters. Outlined in (A) are glucocorticoids, outlined in (D) are cephalosporins.
* indicates compounds which appear in Table 1 or 2.

FIGURE 2

3.1 | Antibiotics

compounds that showed the highest fold-increase in transfection at 50

Six antibiotics showed among the largest fold-decreases in transfection

mM (Table 2), with fold-changes of 1.99, 0.72, 1.26 and 1.26, in transfec-

at 50 mM in the screen, including four cephalosporin b-lactams and

tion, cell-count, Hoechst-intensity, and resazurin-intensity, respectively.

two tetracyclines (Table 2), with transfection fold-decreases ranging

From the clustering perspective, a majority of hits in the screened

from 0.017 to 0.139, and associated cell-count and Hoechst-intensity

b-lactam, tetracycline, and macrolide clusters were identiﬁed as hits

fold-changes ranging from 1.08 to 1.75-fold increase and 0.78 to 0.88-

that showed a signiﬁcant fold-decrease in transfection at 50 mM

fold decrease, respectively. One antibiotic, Eryped, was one of the ten

(Table 3). No antibiotic clusters exhibited a majority of hits decreasing
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transfection at the 5 mM concentration. A majority of the screened ﬂu-
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4 | DISCUSSION

oroquinolones and macrolides were identiﬁed as hits that produced signiﬁcant fold-increase in transfection at 50 mM (Table 3), and a majority

Nonviral gene delivery methods are not currently competitive with viral

of the screened ﬂuoroquinolones, macrolides, and tetracyclines demon-

transduction in clinical trials.10 Pharmaceutical priming has been shown

strated signiﬁcant fold-increase in transfection at 5 mM (Table 3).

to improve transfection eﬃciency,11–19 although in the case of glucocorticoids for example, their priming mechanisms are not well under-

3.2 | Flavonoids and stilbenoids

stood. Transfection priming eﬀects of certain compounds are also likely
to be cell type and carrier speciﬁc, so there is a need to search for

Four of the ten compounds that showed the largest fold-decrease in
transfection at 50 mM in the screen are ﬂavonoids (Table 2), with transfection fold-decreases ranging from 0 to 0.36, and associated cell-

more classes of priming compounds to generate a library of transfection priming candidates and better understand tunable priming mechanisms. Preliminary research into transfection priming should seek

count and Hoechst intensity fold-changes ranging from 0.8 to 1.68-

compounds that have a low development cost and are known to be

fold and 0.86 to 0.87-fold, respectively. One of these ﬂavonoids,

biocompatible and bioavailable. The particular collection of pharmaco-

EGCG, also showed 0.08, 1.37, and 0.88 fold-changes in transfection,

logical compounds screened was the NCC from the NIH Small Mole-

cell-count, and Hoechst-intensity, respectively, at 5 mM (Table 1). At 5

cule Repository,20 which is provided to researchers to repurpose

mM, nobiletin was one of the ten compounds that showed the highest

clinically approved pharmaceutical compounds. NCC compounds have

fold-increase in transfection, with fold-changes of 2.08, 0.61, 1.23, and

known drug-like properties, with well-studied bioactivity, making the

1.21 in transfection, cell-count, Hoechst-intensity, and resazurin-

NCC an ideal starting point for a high-throughput screen to discover

intensity, respectively (Table 1).

priming compounds for nonviral gene delivery.

Stilbenoids demonstrated among the highest fold-increases in
transfection observed in the screen. Piceid was one of the ten com-

4.1 | Overall screen results

pounds that showed the highest fold-increase in transfection at 50 mM
(Table 2), with fold-changes of 2.63, 0.69, and 1.17, in transfection,
cell-count, and Hoechst-intensity, respectively, while resveratrol was
one of the ten compounds that showed the highest fold-increases in
transfection at 5 mM (Table 1), with fold-changes of 3.04 and 0.55, in
transfection and cell-count, respectively.

Of the 725 NCC compounds screened for their eﬀect on transfection,
hundreds had signiﬁcant eﬀects on transfection at 5 or 50 mM doses,
of which the most eﬀective priming compounds were identiﬁed and
examined for clustered eﬀects of several drug classes. The highest concentration tested in this screen was 50 lM, which was based on a previous high throughput screen that similarly screened, in vitro, for novel

3.3 | GABAA receptor modulators

chemoprotective compounds at 50 lM.24 Additional concentrations at
orders of magnitude lower concentration (5 and 0.5 lM) were consid-

GABAA receptor modulators demonstrated among the highest fold-

ered in order to test for compounds which require more dilute concen-

increases to transfection in the screen at both 5 and 50 mM. No

trations to aﬀect transfection fold-changes with minimal cytotoxicity.

GABAA receptor modulators were identiﬁed as hits for fold-decreases

In preliminary screens carried out at 0.5, 5, and 50 lM in our lab (data

in transfection. Stiripentol was one of the ten compounds that showed

not shown), the majority of potential hits were identiﬁed at 5 and 50

the highest fold-increase in transfection at 50 mM (Table 2), with fold-

lM, therefore, these two concentrations were chosen for the complete

changes of 1.77, 0.72, and 1.23, in transfection, cell-count, and

NCC screen.

Hoechst-intensity, respectively. Zolpidem tartrate and nitrazepam were

It must be emphasized that within this screen, the priming com-

two of the ten compounds that showed the highest fold-increase in

pounds and PEI/DNA complexes were in fact not added at the same

transfection at 5 mM (Table 1), with fold-changes of 3.05 and 2.03, and

time, with the priming compounds delivered to cells 1 hr prior to deliv-

0.52 and 0.53, in transfection and cell-count, respectively. From the

ery of the PEI/DNA complexes. This timing was selected based on pre-

clustering perspective, a majority of the compounds in the GABAA

vious studies,15–19 which demonstrated that priming compound eﬀects

modulator cluster were hits exhibiting fold-increases in transfection at

do not require codelivery with the transfection, and in fact were often

5 mM (Table 3).

most potent when applied in a short window of time, including the 1hr time point, prior to transfection. The screen was conducted in dupli-

3.4 | Hormones

cate (n 5 2) with normalization of transfection measures to minimize
artifacts.

The hormone cluster had the most member compounds of all clusters

Preliminary veriﬁcation experiments were performed for three of

in the NCC collection, with 54 members, 30 of which are glucocorti-

the priming compounds identiﬁed: resveratrol, corticosterone, and epi-

coids. From the clustering perspective, the majority of glucocorticoids

gallocatechin gallate. Resveratrol and EGCG were chosen to verify anti-

and hormones demonstrated fold-increases in transfection at 5 mM

oxidants, a drug class that demonstrated among the largest

(Table 3). However, hormones were not among the compounds with

transfection fold-changes observed in the screen; furthermore, these

largest fold-increases or fold-decreases in transfection in the screen

two drugs demonstrated opposite eﬀects on transfection, given resver-

(Tables 1 and 2).

atrol was shown to increase transfection in the screen (3-fold at 5 lM),
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while EGCG knocked down transfection (13-fold at 5 lM) in the

vonoid nobileton showed 2-fold increase in transfection at 5 mM,

screen. Corticosterone was chosen as one of the glucocorticoid hor-

among the largest in the screen. Conversely, several ﬂavonoids were

mones in the NCC, a large class of priming compounds that exhibited

among compounds with largest fold-decrease in transfection at 50 mM;

modest transfection fold-increases (corticosterone: 1.5-fold at 5 lM) in

EGCG exhibited the most potent fold-decrease in transfection of the

the screen. In the veriﬁcation experiments, these compounds were

screen at both 5 and 50 mM, with fold-decreases of 0.08 and 0, and

tested in triplicate at 5 lM, with resveratrol exhibiting approximately

cell-count fold-changes of 1.37 and 0.8, respectively (Tables 1 and 2).

5-fold increase in transfection relative to control, corticosterone exhib-

The stilbenoids resveratrol and piceid, at 5 and 50 mM, respectively,

iting approximately 3.5-fold increase, and EGCG exhibiting 38-fold

exhibited nearly 3-fold increases in transfection, which were among

decrease; these further experiments agree with the screen results (see

the largest seen in the screen.
Like antibiotics, antioxidant transfection priming eﬀects observed

Supporting Information Figures S1 and S2).
There was a negative correlation in screen hits between transfec-

in the screen can potentially be explained by interactions with mito-

tion fold-increases and cell-count fold-change, which may be related to

chondria, however, in a manner that generally protects or improves

interference of priming compounds with normal cell processes, or

their function.29 Resveratrol is a natural phenol, speciﬁcally a stilbenoid,

increased toxicity of EGFP as it is overproduced due to priming. Drug

with antioxidant properties, that can be found in grape skins.29 Piceid

clustering results indicate that certain compounds may be modulating

is a another plant-derived stilbenoid, speciﬁcally a glucoside modiﬁca-

the cell response to PEI transfection; those clusters include antibiotics,

tion of resveratrol. Resveratrol has been shown to rescue mitochon-

antioxidants, GABAA modulators, and glucocorticoids, as discussed

drial dysfunction and modulate autophagy,30 which could be beneﬁcial

next.

by mitigating the cytotoxic eﬀects of PEI transfection,28 from PEI’s
toxic interactions with mitochondria, to oxidative stress induced by
transgene expression.16–19,31 If antioxidants are modulating transfec-

4.2 | Antibiotics

tion through mitochondria and oxidative stress response,32 the
From the results of the screen, antibiotic priming compounds were

observed antioxidant priming eﬀects that potently increase or decrease

shown to aﬀect transfection, with many showing potent inhibition

transfection provide additional evidence that the cellular stress

(Table 2). Many protocols recommend transfection in medium without

response to transfection is critical to overall transfection outcome,16–18

antibiotics, as they are thought to decrease transfection or cell viabil-

a response that is tunable by priming.

ity.25,26 However, among the antibiotics in the NCC, antibiotic eﬀects
on transfection were observed to be dose and antibiotic-class dependent. At 50 mM, the majority of cephalosporin- and tetracycline-class

4.4 | GABAA receptor modulators

antibiotics screened resulted in large fold-decreases in transfection

Like antibiotics and antioxidants, GABAA modulators were also identi-

(Table 3), while the ﬂuoroquinolone-class did not show transfection

ﬁed by the screen as compound clusters in the NCC that resulted in

fold-decreases at 50 mM. At 5 mM, the majority of antibiotics in the

large transfection fold-changes, with the majority of GABAA modula-

ﬂuoroquinolone-, macrolide-, and tetracycline-class clusters resulted in

tors (seven of nine compounds) increasing transfection at the 5 mM

transfection fold-increases; the majority of b-lactam/cephalosporin

concentration. Zolpidem, nitrazepam, and stiripentol were identiﬁed to

cluster antibiotics did not prime transfection fold-increases at 5 mM.

cause among the highest transfection fold-increases in in the screen: 3,

The mechanisms that cause the transfection priming eﬀects of
antibiotics observed in the screen may be related to the primary oﬀ27

target of antibiotics in mammalian host cells, which is mitochondria.

Modulation of mitochondrial dysfunction and oxidative stress response
could explain the eﬀects antibiotics have on transfection, particularly
when utilizing transfection reagents that are known to aﬀect mitochondria, such as PEI. PEI has been shown to cause mitochondrial dysfunction through disruption of the mitochondrial membrane that can result
28

in oxidative stress and apoptosis.

If the identiﬁed antibiotic classes

are inducing their priming eﬀects through interaction with mitochondria, it would be evidence that PEI-induced mitochondrial dysfunction
and associated autophagy can be modulated to either increase or
decrease transfection by design of the priming compound.

2, and 1.7-fold, respectively (Tables 1 and 2).
GABAA receptors are neurotransmitter receptors that are not
expressed in most cell types, so the mechanism behind priming eﬀects
seen with the GABAA modulator cluster is not immediately apparent.
Benzodiazepines, stiripentol, and zolpidem are positive allosteric modulators of the GABAA receptor found in neurons, however, they are
thought to act on diﬀerent subunits.33,34 The GABAA receptor, or
some of the subunits, may be expressed in HEK293T cells, a plausible
possibility due to the proposed adrenal cortex origin of the HEK293T
cell line,35 which may explain the observed transfection priming eﬀects
of GABAA modulators in the screen, although the potential mechanism
of interaction between GABAA receptor modulation and transfection
is not clear.
Another possibility that may explain the transfection priming

4.3 | Flavonoid and stilbenoid compounds

eﬀects of GABAA modulators is interaction with the translocator protein, also known as the peripheral benzodiazepine receptor, which is

The priming eﬀects observed in antioxidants tested from the NCC in

found in mitochondria membranes, and is thought to be involved in

this screen provide further evidence that modulation of mitochondrial

steroidogenesis and redox regulation of mitophagy.36,37 This interac-

dysfunction is a potent priming mechanism of PEI transfection. The ﬂa-

tion would be consistent with the concept of modulating mitochondrial

NGUYEN

|

ET AL.

133

dysfunction and cellular stress response to transfection as the mecha-

PEI has been shown to be cytotoxic through its accumulation in

nism by which priming is occurring through antibiotics and antioxidants

and interaction with mitochondrial membranes.28 Damage to mito-

(see above).

chondria has been implicated in the intracellular inﬂammatory and
immune response42,43; PEI has been shown to be an eﬀective adjuvant
for stimulating an immune response.44 Typical cellular responses to

4.5 | Glucocorticoids and other hormones

mitochondrial damage are autophagy/mitophagy, apoptosis, and necro-

Finally, the eﬀects of glucocorticoids and other hormones in the NCC

sis. Apoptosis and autophagy are mutually inhibitory,45 with apoptosis

were examined, as glucocorticoids have previously shown enhance-

leading to cell death, while autophagy possibly serves a protective role

ment of lipoplex-mediated transfection in hMSCs by over 10-fold.15

in PEI cytotoxicity.46

The hormone cluster was the largest cluster of drugs in the NCC, and

Altogether, literature review of grouped screen hit compounds

the majority of these hormones were glucocorticoids (Figure 2). In this

suggests that many priming eﬀects may be due to modulation of the

screen, the majority of hormones, and glucocorticoids speciﬁcally,

cellular oxidative stress response to PEI transfection, in particular mito-

increased transfection at the 5 mM concentration, with average 1.4-

chondrial dysfunction. It is plausible that certain antioxidants like

fold increases in transfection. This transfection fold-change is much

resveratrol29,30 rescue the cell from PEI-induced mitochondrial dys-

15

indicating

function through modulation of autophagy, improving transfection,

priming eﬀects for at least certain compounds are dependent on cell

while certain antibiotics that reduce transfection, such as cephalospo-

type and/or transfection reagent.

rins,47 may be inhibiting transfection by increasing mitochondrial dys-

less than the 10-fold increases seen previously in hMSCs

There are several plausible explanations for the transfection pri-

function and oxidative stress.

ming fold-increases observed in glucocorticoids and other hormones in

Gene expression proﬁling has shown that there is diﬀerential

this screen. Glucocorticoids are hormones that are involved in the

expression in the cellular oxidative stress response associated with suc-

body’s stress response, activating the glucocorticoid receptor, which

cessfully versus unsuccessfully PEI-transfected cells, through ATF3,

translocates to the nucleus and acts as a transcription factor.15 Upregu-

IREB2, and other gene pathways.16–19 The high-throughput screen

lation of certain genes by activated hormone receptors in response to

data in this current study support this ﬁnding, and suggest that modu-

priming by hormones may play a role in the observed transfection fold-

lating the cellular stress response to PEI transfection by priming with

changes in the screen, as it has previously been shown in gene expres-

clinically approved compounds prior to PEI transfection can signiﬁ-

sion proﬁling studies that pharmacological priming of genomic targets

cantly aﬀect overall transfection eﬃciency and transgene expression in

16–19

can aﬀect transfection.

Activated glucocorticoid receptors may

vitro.

also play a role in priming transfection by assisting internalization,
nuclear transport, and nuclear import of transfection complexes.

5 | CONCLUSIONS

Finally, glucocorticoid priming eﬀects in PEI transfection could be
occurring through interaction with mitochondria and autophagy,38,39

With a high-throughput, drug-repurposing, and bio/cheminformatics

which would be further evidence that aligns with the hypothesis that

clustering approach, this screen of the NCC identiﬁed many individual

modulation of PEI transfection toxicity and cellular stress response are

compounds that produce dramatic fold-changes in HEK293T transfec-

the priming mechanisms for antibiotics, antioxidants, and GABAA

tion by PEI, and several classes of clinical drugs for which the majority

clusters.

of compounds demonstrated priming eﬀects. These hit compounds
and drug clusters should be veriﬁed and studied for investigation of

4.6 | Mitochondrial dysfunction, oxidative stress, and
autophagy in PEI transfection

the priming mechanisms in detail that will improve our understanding

PEI is a cationic polymer carrier for nonviral gene delivery that serves

data suggest that several of these drug classes, such as stilbenoids and

as a standard to which newly developed carriers are often compared,

ﬂavonoid antioxidants, cephalosporin antibiotics, GABAA receptor

as it reliably overcomes the primary barriers to transfection of cultured

modulators, and others, may be priming transfection through modula-

mammalian cells: internalization, endosomal escape, and nuclear trans-

tion of mitochondrial dysfunction, oxidative stress, and cell death proc-

port,8 although not with the eﬃciencies found in viral vectors.9 Para-

esses caused by toxicity of PEI transfection. These compounds and

doxically, PEI designs that are more eﬀectively able to overcome

drug classes should be tested on additional cell types with alternative

barriers to transfection also tend to be more toxic to the transfected

nonviral carriers to generalize the priming eﬀects towards potential

cell. For instance, high molecular weight (MW) and branched PEI com-

application as transfection adjuvants. For future in vivo studies, the 5

plexes have been demonstrated to transfect at higher eﬃciencies com-

and 50 lM concentrations can serve as starting points in the optimiza-

40,41

of the cellular response to transfection and how this response can be
pharmacologically modulated to improve transfection. The clustered

but also exhibit higher

tion of the delivery method and dose and release characteristics of

toxicity. Attempts to resolve this dilemma include bioresponsive link-

each priming compound to maximize transfection priming eﬀects. Addi-

ages of low MW PEI into higher MW PEI-based polymers that will

tionally, timing of the addition of the priming compound relative to the

pared to low MW and linear PEI complexes,

40

degrade in the cell into less toxic lower MW constituents.

DNA should be studied more extensively as a tunable priming
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parameter. Resveratrol and zolpidem had the highest fold-change
increases observed in the screen, at 3-fold; the potency of their priming
eﬀect indicates their mechanisms may be critical to understanding how
nonviral gene delivery can be improved by priming.
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